NewAmsterdam Pharma Co N.V. - 8-K Filing

NewAmsterdam Pharma Co received EU marketing authorization for Ubeslo and Evlarco containing obicetrapib on September 21, 2026. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $NAMS

Read the full article at SEC EDGAR

More Regulatory news